Nucleoside reverse transcriptase inhibitors (NRTIs) for HIV - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Nucleoside reverse transcriptase inhibitors (NRTIs) for HIV - [Medication] - Quest Diagnostics Patient Health Library Nucleoside reverse transcriptase inhibitors (NRTIs) for HIV - [Medication] - Quest Diagnostics Patient Health Library Immune system,...
A to Z List - Medication Information A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z - A Abacavir Abacavir, lamivudine, zidovudine Acyclovir Alendronate Allopurinol Amifostine Amitriptyline Amlodipine Amoxicillin Amoxicillin / clavulanic acid Amphotericin B Ampicillin Amprenavir Anti-thymocyte globulin Asparaginase Atenolol Atovaquone Atracurium Azithromycin top - -...
author: St. Jude Children's Research Hospital
Patient Information Drug Information Sheet for Patients Antiretroviral Drug Classes Nucleoside Analogue Reverse Transcriptase Inhibitors 2,3-Dideoxycytidine (ddC, Hivid®) Abacavir (1592U89, Ziagen®) Abacavir (Ziagen) Hypersensitivity Reaction -- Didanosine(DDI, VIDEX® chew tabs, VIDEX® EC) - Lamivudine (3TC, Epivir®) (Combivir ® - with AZT) Stavudine (d4T, Zerit&...
http://www.fda.gov/cder/orange/appendix_a.txt 12, CHLORPHENIRAMINE MALEATE (OTC) CODOXY, ASPIRIN CODRIX, ACETAMINOPHEN COGENTIN, BENZTROPINE MESYLATE COGNEX, TACRINE HYDROCHLORIDE COL-PROBENECID, COLCHICINE COLAZAL, BALSALAZIDE DISODIUM COLBENEMID, COLCHICINE COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC) COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC) COLESTID, COLESTIPOL HYDROCHLORIDE COLGATE TOTAL, SODIUM FLUORIDE (OTC)...
Combivir Combivir ® ; Lamivudine & Zidovudine ; (-)-3TC & AZT Although resistance to Zidovudine frequently develops, the addition of Lamivudine to a therapeutic regimen can cause AZT-resistant strains to revert to AZT-sensitive strains (1)Combivir ® combines 150 mg of Lamivudine and 300 mg of Zidovudine into a single tablet that is...
Drug Index L-ascorbic acid ; AA; Calcium Ascorbate L-Chicoric acid ; Dicaffeic acid ester L-D4A ; L-2',3'-Didehydro-2',3'-dideoxyadenosine L-D4FC ; L-2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine L-D4G ; L-2',3'-Didehydro-2',3'-deoxyguanosine L-D4I ; L-2',3'-Didehydro-2',3'-dideoxyinosine L-FddC ; b-L-5F-ddC Lamivudine ;Epivir®; 3TC; Approved Lamivudine & Zidovudine ; ...
Drug Index L-ascorbic acid ; AA; Calcium Ascorbate L-Chicoric acid ; Dicaffeic acid ester L-D4A ; L-2',3'-Didehydro-2',3'-dideoxyadenosine L-D4FC ; L-2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine L-D4G ; L-2',3'-Didehydro-2',3'-deoxyguanosine L-D4I ; L-2',3'-Didehydro-2',3'-dideoxyinosine L-FddC ; b-L-5F-ddC Lamivudine ;Epivir®; 3TC; Approved Lamivudine & Zidovudine ; ...
Zidovudine (AZT, Retrovir®) ZIDOVUDINE (AZT, Retrovir®)(Combivir® - with Lamivudine, Trizivir® with Lamivudine and Abacavir) What is AZT
Lamivudine (3TC ®) LAMIVUDINE (3TC ®)(Combivir® - with Zidovudine, Trizivir ® with Zidovudine and Abacavir) What is 3TC
V:\DAVDP\CSO\HOLLOMAN\NDAS\NDA 19655 RETROVIR CAPS\AP LETTER with \ ATTACHED LABELING 10-14-2003 SLR-039.doc Zidovudine Pharmacokinetic Parameters in Patients With Severe Renal Impairment * Parameter Control Subjects (Normal Renal Function) (n = 6) Patients With Renal Impairment (n = 14) CrCl (mL/ min) 120 ± 8 18 ± 2 Zidovudine AUC (ng° hr/ mL) 1,400 ± 200 3,100 ± 300 Zidovudine half- life (hr) 1.0 ± 0.2 1.4 ± 0.1 * Data are expressed as...
author: Marsha Holloman
V:\DAVDP\CSO\HOLLOMAN\NDAS\NDA 19951 RETROVIR IV\SLR-019 DOCS\AP \ LTR with LABELING 07-17-2003 SLR-019.doc Drug Interactions: See Table 4 and PRECAUTIONS: Drug Interactions: Zidovudine Plus Lamivudine: No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12 asymptomatic HIV- infected adult patients given a single oral dose of zidovudine (200 mg) in combination with multiple oral doses of lamivudine (300 mg every 12 hours)
author: Marsha Holloman
V:\DAVDP\CSO\HOLLOMAN\NDAS\NDA 19951 RETROVIR IV\SLR-018 DOCS\AP \ LTR with LABELING 07-17-2003 SLR-018.doc NDA 19- 951 RETROVIR IV Infusion Page 7 Table 2: Zidovudine Pharmacokinetic Parameters in Patients With Severe Renal Impairment* Parameter Control Subjects (Normal Renal Function) (n = 6) Patients With Renal Impairment (n = 14) CrCl (mL/ min) 120 ± 8 18 ± 2 Zidovudine AUC (ng° h/ mL) 1400 ± 200 3100 ± 300 Zidovudine half- life (h) 1.0 ±...
author: Marsha Holloman
http://www.fda.gov/cder/foi/label/2001/20564s13lbl.pdf EPIVIR lamivudine tablets) EPIVIR olution ( lamivudine oral solution) 4 Table 1: Pharmacokinetic Parameters ( Mean ± D) fter a ingle 300- mg Oral Dose of Lamivudine in 3 Groups of dults With Varying Degrees of Renal Function Creati i e Cleara e Criterio (Number of Subje ts) Parameter >60 mL/ mi ( 6) 10- 30 mL/ mi ( 4) <10 mL/ mi ( 6) Creati i e leara e ( mL/ mi ) 111 ±...
http://www.fda.gov/cder/foi/label/2001/20596s13lbl.pdf EPIVIR lamivudine tablets) EPIVIR olution ( lamivudine oral solution) Figure 1: Mean bsolute CD4 Cell Count Change ( cells/ mm 3 ) From Baseline in tudy 3001 Figure 2: Mean Change From Baseline in Plasma HIV RN log10 copies/ mL) in tudy 3001 EPIVIR lamivudine tablets) EPIVIR olution ( lamivudine oral solution) Figure 3: Mean bsolute CD4 Cell Count Change ( cells/ mm 3 ) From Baseline...
APPROVED LABELING NDA 20-596/S-012 Figure 1: Mean bsolute CD4 Cell Count Change ( cells/ mm 3 ) From Baseline in tudy 3001 EPIVIR lamivudine tablets) EPIVIR olution ( lamivudine oral solution) 7 Figure 2: Mean Change From Baseline in Plasma HIV RN log10 copies/ mL) in tudy 3001 Figure 3: Mean bsolute CD4 Cell Count Change ( cells/ mm 3 ) From Baseline in tudy B3001 Ther py- Experienced Adults ( 24 Weeks of rior ...
author: JFG
subject: EPIVIR (LAMIVUDINE) TABLETS AND ORAL SOLUTION
V:\DAVDP\CSO\LYNCHE\LYNCHES\NDA\21453\Letters\21453applt+labelin\ g.doc Drug Interactions (see PRECAUTIONS: Drug Interactions) Zidovudine competitively inhibits the intracellular phosphorylation of stavudine
author: Marsha Holloman
V:\DAVDP\CSO\HOLLOMAN\NDAS\NDA 19655 RETROVIR CAPS\AP LETTER with \ ATTACHED LABELING 12-09-2002 SLR-038.DOC Zidovudine Pharmacokinetic Parameters in Patients With Severe Renal Impairment* Parameter Control Subjects (Normal Renal Function) (n = 6) Patients With Renal Impairment (n = 14) CrCl (mL/ min) 120 ± 8 18 ± 2 Zidovudine AUC (ng° hr/ mL) 1,400 ± 200 3,100 ± 300 Zidovudine half- life (hr) 1.0 ± 0.2 1.4 ± 0.1 *Data are expressed as...
author: Marsha Holloman
Virco Drugs and Resistance - Despite the availability of up to 16 drugs to fight HIV infections, many treatments fail in the long run. Resistance to these drugs is one of the leading causes of treatment failure. ...
Virco - Home About News Virco Services Healthcare Professionals PLWHA Pharma Services HIV Information FAQs Contact ---General--- ---TDM--- - ---Global HIV epidemic--- ---HIV Dynamics--- ---HIV Variation--- ---Drugs ...
ACL-Heilek-Snyder-HIV-Oct02-l/o For instance, there are now computerized analyses of current genotype databases that can answer questions regarding the frequency of specific combinations of mutations occurring in differ The benefits of HIV resistance testing in optimizing drug discovery BY GABRIELLE HEILEK- SNYDER AND PAMELA BEAN Table 1 FDA- approved drugs for the treatment of HIV/ AIDS* Nucleoside analog reverse...
author: Rachel Domack
ACL-Heilek-Snyder-HIV-Oct02-l/o page 1
author: Rachel Domack
Research Studies Lamivudine 150mg BID in Combination with Zidovudine 300mg BID and Efavirenz 600mg Once Daily in Antiretroviral Naive Adults with HIV-1 InfectionLamivudine and Zidovudine or Stavudine)...
V:\DAVDP\CSO\KELLY\NDA\20857\LETTERS\AP012.doc NDA 20- 857/ S- 009,010 Page 3 PRESCRIBING INFORMATION COMBIVIR (lamivudine/ zidovudine) Tablets WARNING ZIDOVUDINE, ONE OF THE TWO ACTIVE INGREDIENTS IN COMBIVIR, HAS BEEN ASSOCIATED WITH HEMATOLOGIC TOXICITY INCLUDING NEUTROPENIA AND SEVERE ANEMIA, PARTICULARLY IN PATIENTS WITH ADVANCED HIV DISEASE (SEE WARNINGS)Lamivudine Blood...
author: Vasavi Reddy
V:\DAVDP\CSO\KELLY\NDA\20857\LETTERS\AP012.doc page 19
author: Vasavi Reddy
V:\DAVDP\CSO\KELLY\NDA\20857\LETTERS\AP012.doc page 14
author: Vasavi Reddy
